Friday, January 10, 2014

Graubert appointed first incumbent of the Hagler Family Chair

ADVANCING TREATMENT: From left, Daniel Haber, MD, PhD, director of the Cancer Center; Graubert; Jo Ann and Jon Hagler; Katrina Armstrong, MD, chief of the Department of Medicine; Slavin; and Ryan.

Timothy A. Graubert, MD, program director for Hematologic Malignancies at the MGH Cancer Center, was honored Nov. 18 with the first Hagler Family Chair in Hematologic Malignancies. The reception also celebrated the establishment of the Jon and Jo Ann Hagler Center – integrating clinical care, research and support services to provide care for patients diagnosed with Non-Hodgkin and Hodgkin lymphomas. The chair and center were established through a gift from the Haglers.

“The Hagler Family Chair made it possible for us to recruit Dr. Tim Graubert,” said MGH President Peter L. Slavin, MD. “Tim is a leading authority in the genetics of acute myeloid leukemia and myelodysplastic syndromes. With his background and expertise, I feel confident that Tim and his team will tailor the tools of personalized medicine to advance the treatment of hematologic malignancies.”

The ceremony at the Paul S. Russell, MD Museum of Medical History and Innovation was attended by members of the Hagler and Graubert families and included remarks from Jeremy Abramson, MD, clinical director of the MGH Center for Lymphoma, and David Ryan, MD, chief of Hematology/Oncology, who introduced Graubert.

“Dr. Graubert will provide oversight for the leukemia, lymphoma, myeloma and bone marrow transplantation programs, with the major objective of developing and unifying a research agenda that will help translate new laboratory discoveries to the clinic,” said Ryan. “He will lead an expanded team through the execution of a concerted effort to advance treatment for hematologic malignancies into the realm of personalized medicine.”

Prior to joining the Cancer Center in October, Graubert was associate professor in the Department of Medicine at Washington University in St. Louis. As a leading authority in the field of targeted therapies for cancer and a pioneer in the use of genome sequencing technology, his laboratory and clinical work focuses on the identification of new genes that confer increased susceptibility to myeloid leukemia and genes that, when mutated, somatically cooperate with inherited variants to result in leukemia.

“I am honored to be the first incumbent for the Hagler Family Chair in hematologic malignancies,” said Graubert. “I look forward to working with my colleagues in the Hematologic Malignancy Program at the MGH to improve the care we provide for our patients.” 

Read more articles from the 01/10/14 Hotline issue.



Back to Top